This work provides important insight into the mechanisms of response and resistance to targeted cancer treatment approaches in general, and particularly for renewed efforts to therapeutically target Ras signaling.41 Furthermore, our results support further characterization of RALB signaling as a key mediator of survival and NRAS-independent relapse in AML and as a valid therapeutic target. This evidence concerns the gene NRAS and acute myeloid leukemia.